GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

August 31, 2009

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

GV 1001 Telomerase peptide

Trial Locations (1)

Rikshospitalet - Radiumhospitalet HF, Oslo

All Listed Sponsors

collaborator

St. Olavs Hospital

OTHER

collaborator

Sorlandet Hospital HF

OTHER_GOV

lead

Oslo University Hospital

OTHER

NCT00509457 - GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter